2025
SJR Q1
JCR Q1 · 5
OA
17 matched articles
SCIE
Journal detail
Therapeutic Advances in Psychopharmacology
- Publisher
- SAGE Publications Inc.
- Country
- United Kingdom · Western Europe
- Type
- journal
- ISSN
-
2045125320451261
Integrated evaluation
Scopus side is Scimago SJR; WoS side is Master Journal List + JCR/JIF. Sources are matched on ISSN. WoS / JCR metrics are available for 1997 and later years only.
WoS / JCR data covers 1997 onward.
Scopus
Scopus · Scimago
- SJR 1,321
- Quartile Q1
- H-Index 52
- Cites/doc 4,39
- Docs (3y) 111
- Cites (3y) 461
Clarivate
Web of Science · JCR · 2025
- JCR Q Q1
- JIF 5
- 5Y JIF 4,5
- JCI 0,77
WoS indexes
- SCIE
Subject classification
Categories (SJR)
- Pharmacology (medical) Q1
- Psychiatry and Mental Health Q1
Areas
- Medicine
WoS categories
- Pharmacology & Pharmacy | Psychiatry
Yearly quartile comparison
Scimago (SJR) for all years; Clarivate (JCR / JIF / JCI) from 1997 onward. Latest year stays open; older years start collapsed.
WoS / JCR data covers 1997 onward.
| Year | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q1 | Q1 | 1,321 | 5 | 4,5 | 0,77 | Q2 | 52 |
| 2024 | Q1 | Q1 | 1,187 | 4 | 4,2 | 0,79 | Q2 | 46 |
| 2023 | Q1 | Q2 | 1,179 | 3,4 | 4,3 | 0,76 | Q2 | 46 |
| 2022 | — | Q2 | — | 4,2 | 4,6 | 0,74 | Q2 | 46 |
| 2021 | — | Q2 | — | 5 | 5 | 0,77 | Q2 | 46 |
| 2020 | — | Q1 | — | 5 | 4 | 0,69 | Q2 | 46 |
| 2019 | — | Q2 | — | 3 | — | 0,63 | Q3 | 46 |
| 2018 | — | Q2 | — | 3 | — | 0,6 | Q3 | — |
| 2017 | — | — | — | — | — | — | — | 46 |
| 2016 | — | — | — | — | — | — | — | 46 |
| 2015 | — | — | — | — | — | — | — | 46 |
| 2014 | — | — | — | — | — | — | — | 46 |
| 2013 | — | — | — | — | — | — | — | 46 |
| 2012 | — | — | — | — | — | — | — | 46 |
| 2011 | — | — | — | — | — | — | — | 46 |
JCR category quartile history
JCR / JCI quartile by year and category. 1997 and later.
WoS / JCR data covers 1997 onward.
| Year | Category | Edition | JCR Q (1997+) | JCI Q (1997+) | Rank |
|---|---|---|---|---|---|
| 2025 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q2 | 70/356 |
| 2025 | PSYCHIATRY | SCIE | Q1 | Q2 | 41/293 |
| 2024 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q2 | 83/352 |
| 2024 | PSYCHIATRY | SCIE | Q1 | Q2 | 54/288 |
| 2023 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 105/354 |
| 2023 | PSYCHIATRY | SCIE | Q2 | Q2 | 79/279 |
| 2022 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 91/278 |
| 2022 | PSYCHIATRY | SCIE | Q2 | Q2 | 64/155 |
| 2021 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 79/279 |
| 2021 | PSYCHIATRY | SCIE | Q2 | Q2 | 58/155 |
| 2020 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q2 | 66/276 |
| 2020 | PSYCHIATRY | SCIE | Q1 | Q3 | 36/156 |
| 2019 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q3 | 109/271 |
| 2019 | PSYCHIATRY | SCIE | Q2 | Q3 | 59/155 |
| 2018 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q3 | 102/267 |
| 2018 | PSYCHIATRY | SCIE | Q2 | Q3 | 59/146 |